Margy Visit 2: 47-Year-Old Woman with Severe Hypertriglyceridemia and Type II Diabetes

0.5 ACPE 0.5 ANCC Contract Hours 0.5 CDR 0.5 AMA PRA Category 1 Credit(s)™
Launch Date:
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Christie M. Ballantyne, MD

Christie M. Ballantyne, MD
Professor of Medicine
Baylor College of Medicine
Section of Atherosclerosis and Vascular Medicine
Maria and Alando J. Ballantyne, MD Atherosclerosis Clinical Research Laboratory
Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart Center
Lipid Metabolism and Atherosclerosis Clinic
The Methodist Hospital
Houston, TX

Christie M. Ballantyne, MD, is Director of the Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center; Chief of the Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine; Director of the Maria and Alando J. Ballantyne, MD, Atherosclerosis Laboratory; Professor of Medicine with a joint appointment in Pediatrics, Baylor College of Medicine; and Co-Director, Lipid Metabolism and Atherosclerosis Clinic, The Methodist Hospital, Houston, Texas. He received his Doctor of Medicine from Baylor College of Medicine, and his postgraduate training included an internal medicine residency at The University of Texas Southwestern Medical School, Dallas, Texas, a cardiology fellowship at Baylor College of Medicine, and an American Heart Association/Bugher Foundation Fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor. 

Dr. Ballantyne is a Fellow of the American Association for the Advancement of Science, member of the American Society for Clinical Investigation, Fellow of the American College of Cardiology, and Fellow of the American College of Physicians. He previously served as governor of the Texas Chapter of the American College of Cardiology and president of the Houston Chapter of the American Heart Association. Dr. Ballantyne has been the recipient of numerous study grants, including an American Heart Association Established Investigator Award and several NIH grants to study leukocyte–endothelial adhesion molecules and novel biomarkers for atherosclerosis. 

He has been a member of numerous steering committees for multicenter trials, including the Atherosclerosis Risk in Communities (ARIC) study, Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE IT), A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID), National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II (NEPTUNE II), and Effect of Niacin ER/Lovastatin on Peak Walking Time and Claudication Onset Time in Patients With Intermittent Claudication (ICPOP), and has also participated as a member of several Data and Safety Monitoring Boards. Dr. Ballantyne is Editorial Director for He has published extensively and has spoken nationally and internationally on lipids, atherosclerosis, and inflammation. Dr. Ballantyne's research interests include the pathophysiology of atherosclerosis, with an emphasis on monocyte activation and adhesion. His clinical interests include preventive cardiology, lipids, metabolic syndrome, atherosclerosis, genetics, and coronary artery disease.

Harold E. Bays, MD

Harold E. Bays, MD
Medical Director/President
Louisville Metabolic and Atherosclerosis Research Center, Inc. (L-MARC)
Louisville Endocrinology PSC
Louisville, KY

Harold Bays, MD, FACP, FACE is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC).  Dr. Bays received his medical degree, completed his Internship and Residency in Internal Medicine, and received his Fellowship in Endocrinology and Metabolism all at the University of Louisville School of Medicine.  He is board certified in both Internal Medicine and Endocrinology and Metabolism.  Dr. Bays has served as a Principal Investigator for over 400 clinical trials, including studies of all currently marketed lipid-altering drug treatments, as well as studies of investigational drugs for obesity, diabetes mellitus, hypertension, osteoporosis, osteoarthritis, and other metabolic disorders.  He has written, or has been a contributing author to over 100 scientific manuscripts and book chapters, and been an author of over 100 scientific abstracts.  Dr. Bays has served as an expert manuscript reviewer for over 40 scientific medical journals and serves as an international advisor and consultant to pharmaceutical companies in drug development.

Dr. Bays is a Fellow of NAASO/The Obesity Society, a Fellow of the American Association of Clinical Endocrinologists, a Fellow of the American College of Physicians (FACP), a member of the Endocrine Society, the National Lipid Association, the American Diabetes Association, the American Medical Association (AMA), the Kentucky Medical Association (KMA), and the Greater Louisville Medical Society.

Tara Lynn Dall, MD

Tara Lynn Dall, MD
Medical Director/President
Advanced Lipidology
Delafield, WI

Tara Dall, MD graduated in the first class of Diplomates of the American Board of Clinical Lipidology. She was Board-Certified in Clinical Lipidology November 2005, and is one of a handful of United States physicians treating pediatric dyslipidemia. Her clinic has recently become the first fully certified lipid clinic in the United States.  She attended University of Wisconsin Madison for undergraduate, medical school training and family medicine residency. Entering private practice in 2001, she formed the Cholesterol & Lifestyle Center in 2006 with the goal of aggressive detection and treatment of atherosclerotic cardiovascular disease. In 2008 she formed Advanced Lipidology, SC Early Detection Center for Heart Disease and Diabetes.  She has a special interest in advanced lipid testing and CIMT technology, women's heart disease, polycystic ovarian syndrome and pediatric obesity. She is involved in CIMT research in collaboration with University of Wisconsin Madison and serves as clinical preceptor for Medical College of Wisconsin medicine residents.

Because of her passion and expertise, Dr. Dall has been asked to lecture in every venue from hospital and medical school grand rounds to large scale community events. She also has appeared on CNN Radio, Milwaukee's FOX News, WISN-TV, Reach MD Satellite Radio, RadioHealth Journal and has been a keynote speaker for the American Heart Association GO RED for women community events.

Dr. Dall is an elected board member of the Midwest Lipid Association.  Other hobbies include competitive ballroom dancing and photography.
1. Analyze the therapeutic benefit of nutrition, physical activity, and pharmaceutical agents in the management of patients with combined or mixed dyslipidemia.
2. Compose a clinical care plan for reducing risk of CVD in patients with dyslipidemia.
3. Define treatment goals for patients with mixed dyslipidemia based on the latest guidelines for lipid management issued by the NCEP.
4. Describe the potential effects of elevated triglycerides and non-HDL-C on CVD risk and patient outcomes.